Federal Court Dismisses Compounder's GLP-1 Antitrust Suit Against Eli Lilly and Novo Nordisk Over Telehealth Deals

A federal court has thrown out one of the highest profile legal challenges to the way branded GLP-1 drugs reach patients. In early August 2026, U.S. District Judge Micaela Alvarez dismissed an antitrust lawsuit filed by compounding pharmacy Strive Specialties against Eli Lilly and Novo Nordisk, a case that put the industry's exclusive telehealth partnerships at the center of a fight over access to compounded weight-loss medicines. The ruling is a win for the two drugmakers, but the court dismissed the complaint as pleaded rather than ending the dispute for good.

What the court decided

Strive Specialties, an Arizona based compounding pharmacy, sued Eli Lilly and Novo Nordisk on January 14, 2026, in the U.S. District Court for the Western District of Texas, San Antonio Division (Strive Specialties, Inc. v. Eli Lilly & Co., et al., No. 5:26-cv-1055). The complaint brought federal antitrust claims under the Sherman Act, alleging that the two companies coordinated to suppress competition from compounded GLP-1 products and preserve the market for their branded therapies.

In early August 2026, Judge Alvarez granted the defendants' motion to dismiss. According to reporting on the order, the court found that Strive had not plausibly alleged a relevant antitrust market or the antitrust injury that a Sherman Act claim requires. The dismissal addressed the complaint in its current form, and Strive has said it is weighing whether to file an amended complaint or appeal.

The allegations: telehealth exclusivity at the center

The heart of Strive's case was the distribution channel that connects patients to prescriptions. In the GLP-1 category, that channel runs heavily through telehealth platforms, the same online prescribing model that the FTC targeted in its separate suit against Hims & Hers (see our coverage of the FTC and state lawsuit against Hims & Hers). Strive alleged that Lilly and Novo forged exclusive alliances with telehealth companies under agreements that barred those providers from working with compounders.

Strive alleged that this cut off an essential link between patients holding prescriptions for personalized medicines and the pharmacies that could fill them. Beyond the telehealth deals, the complaint alleged that the drugmakers interfered with compounders' relationships with payment processors and technology and social media platforms, and disparaged compounded medicines as illegal or unsafe. Strive framed the conduct as a coordinated effort to forestall competition and preserve what it called supracompetitive prices. These are allegations that the court did not resolve on the merits; the case was dismissed on threshold antitrust grounds.

Why the case was dismissed: the market-definition problem

Antitrust claims generally require a plaintiff to define a relevant market and show injury to competition within it. According to reporting on the ruling, Judge Alvarez concluded that Strive could not plausibly treat compounded GLP-1 products and branded GLP-1 drugs as part of the same market. The reasoning turned on interchangeability: compounded GLP-1 medications are generally available only to patients who cannot use the branded products as a matter of medical necessity, so the court found they cannot reasonably be understood as interchangeable substitutes for branded drugs like Wegovy and Zepbound.

Without a plausible shared market, the court held that Strive had not shown the kind of antitrust injury needed to move forward. In other words, the case failed on how the market was defined rather than on a finding that the alleged telehealth exclusivity did or did not occur.

The GLP-1 compounding backdrop

The dispute sits on top of a larger shift in the weight-loss drug market. Compounded versions of semaglutide and tirzepatide proliferated while the branded products were in shortage, sold largely through telehealth subscriptions. As the FDA moved the branded drugs off its shortage lists, the legal room for mass compounding narrowed, and manufacturers stepped up enforcement and marketing challenges against compounded and unapproved versions.

That backdrop is why the telehealth channel matters so much to both sides. For compounders, telehealth platforms are the primary way to reach patients. For manufacturers, exclusive or preferred telehealth arrangements are a legitimate distribution strategy for FDA approved products. Strive's suit tried to recast those arrangements as anticompetitive; the court's ruling, at least at the pleading stage, did not accept that framing.

What the ruling does and does not settle

The decision is a significant procedural win for Lilly and Novo, but it is narrow in an important way. The court dismissed the complaint as pleaded on antitrust market and injury grounds. It did not rule that the alleged telehealth exclusivity, payment processor pressure, or disparagement actually happened, and it did not decide whether any of that conduct would be lawful. Because Strive has signaled it may amend or appeal, the questions the case raised about how branded GLP-1 makers use telehealth partnerships could return in this or another lawsuit.

It is also one ruling from one district court. Separate regulatory and enforcement threads, including the FTC's action against a major telehealth platform and manufacturer advertising challenges before the National Advertising Division, continue to shape how compounded GLP-1 products can be marketed and sold.

What this means for telehealth GLP-1 access

This is general information, not legal or medical advice. For patients, the ruling does not change what is legal to prescribe or dispense today; it resolves a private antitrust dispute at the pleading stage. Anyone relying on a compounded GLP-1 product should talk with a licensed clinician about whether an FDA approved option fits their situation, since branded and compounded products sit in different legal and clinical categories. For telehealth companies and compounding pharmacies, the decision signals that reframing manufacturers' distribution and telehealth strategies as antitrust violations faces a high bar at the market-definition stage.